ALK Ligand ALKAL2 Potentiates MYCN-Driven Neuroblastoma in the Absence of ALK Mutation

Scientists tested whether anaplastic lymphoma kinase AL2 (ALKAL2) ligand could potentiate neuroblastoma progression in the absence of ALK mutation
[EMBO Journal]
Borenäs, M., Umapathy, G., Lai, W.-Y., Lind, D. E., Witek, B., Guan, J., Mendoza-Garcia, P., Masudi, T., Claeys, A., Chuang, T.-P., El Wakil, A., Arefin, B., Fransson, S., Koster, J., Johansson, M., Gaarder, J., Van den Eynden, J., Hallberg, B., & Palmer, R. H. (2021). ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation. The EMBO Journal, n/a(n/a), e105784. https://doi.org/10.15252/embj.2020105784 Cite
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share

Nerve Growth Factor Interacts with CHRM4 and Promotes Neuroendocrine Differentiation of Prostate Cancer and Castration Resistance

The authors showed that an androgen-deprivation therapy-stimulated transcription factor, ZBTB46, upregulated NGF via ZBTB46 mediated-transcriptional activation of nerve growth factor.
[Communications Biology]
Chen, W.-Y., Wen, Y.-C., Lin, S.-R., Yeh, H.-L., Jiang, K.-C., Chen, W.-H., Lin, Y.-S., Zhang, Q., Liew, P.-L., Hsiao, M., Huang, J., & Liu, Y.-N. (2021). Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance. Communications Biology, 4(1), 1–14. https://doi.org/10.1038/s42003-020-01549-1 Cite
Full Article
Bookmark

No account yet? Register

0
Share

18F-Meta-Fluorobenzylguanidine (18F-mFBG) to Monitor Changes in Norepinephrine Transporter Expression in Response to Therapeutic Intervention in Neuroblastoma Models

Researchers investigated the potential of 18F-mFBG, a positron emission tomography analogue of the 123I-mIBG radiotracer, to quantify norepinephrine transporter expression levels in mouse models of neuroblastoma following treatment with AZD2014, a dual mTOR inhibitor.
[Scientific Reports]
Turnock, S., Turton, D. R., Martins, C. D., Chesler, L., Wilson, T. C., Gouverneur, V., Smith, G., & Kramer-Marek, G. (2020). 18 F-meta-fluorobenzylguanidine ( 18 F-mFBG) to monitor changes in norepinephrine transporter expression in response to therapeutic intervention in neuroblastoma models. Scientific Reports, 10(1), 20918. https://doi.org/10.1038/s41598-020-77788-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Enhancer Hijacking Determines Extrachromosomal Circular MYCN Amplicon Architecture in Neuroblastoma

Scientists analyzed the MYCN amplicon structure using short-read and Nanopore sequencing and its chromatin landscape using ChIP-seq, ATAC-seq and Hi-C. This reveals two distinct classes of amplicons which explain the regulatory requirements for MYCN overexpression.
[Nature Communications]
Helmsauer, K., Valieva, M. E., Ali, S., Chamorro González, R., Schöpflin, R., Röefzaad, C., Bei, Y., Dorado Garcia, H., Rodriguez-Fos, E., Puiggròs, M., Kasack, K., Haase, K., Keskeny, C., Chen, C. Y., Kuschel, L. P., Euskirchen, P., Heinrich, V., Robson, M. I., Rosswog, C., … Koche, R. P. (2020). Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma. Nature Communications, 11(1), 5823. https://doi.org/10.1038/s41467-020-19452-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

Therapeutic Targeting of KSP in Preclinical Models of High-Risk Neuroblastoma

The authors used human tumor organoids representing multiple MYCN-amplified high-risk neuroblastomas to perform a high-throughput drug screen with approved or emerging oncology drugs.
[Science Translational Medicine]
Hansson, K., Radke, K., Aaltonen, K., Saarela, J., Mañas, A., Sjölund, J., Smith, E. M., Pietras, K., Påhlman, S., Wennerberg, K., Gisselsson, D., & Bexell, D. (2020). Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma. Science Translational Medicine, 12(562). https://doi.org/10.1126/scitranslmed.aba4434 Cite
Abstract
Bookmark

No account yet? Register

0
Share

MYCN Drives Chemoresistance in Small Cell Lung Cancer while USP7 Inhibition Can Restore Chemosensitivity

To study roles for MYCN amplification in small cell lung cancer (SCLC) progression and chemoresistance, we developed a genetically engineered mouse model of MYCN-overexpressing SCLC.
[Genes & Development]
Abstract
Bookmark

No account yet? Register

0
Share

Aberrantly Expressed Bruton’s Tyrosine Kinase Preferentially Drives Metastatic and Stem Cell-Like Phenotypes in Neuroblastoma Cells

Investigators found that Bruton’s tyrosine kinase was highly expressed in primary neuroblastoma samples, preferentially in MYCN-amplified neuroblastoma cases, and was associated with a poor prognosis.
[Cellular Oncology]
Abstract
Bookmark

No account yet? Register

0
Share
Share